Search

Diabetic Retinopathy Header Bar

Editorial Feature:

Diabetic Retinopathy

Changing Treatment Paradigms

Think Outside the Box: Treatment Options for DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Show Description +

Rishi P. Singh, MD; Arshad M. Khanani, MD, MA; and Nancy Holekamp, MD, review why it is important to expand the current treatment options for patients with diabetic retinopathy (DR), along with what we can expect to come down the treatment pipeline in the next 5 years.

Posted: 9/27/2018

Keywords:

Updates in Changing Treatment Paradigms for DR

Up Next in this Program

Anti-VEGF Therapy for Patients With Proliferative and Nonproliferative Disease

Anti-VEGF Therapy for Patients With Proliferative and Nonproliferative Disease

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

Updates in Changing Treatment Paradigms for DR

Translating Data for Educating Patients With DR

Translating Data for Educating Patients With DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Anti-VEGF for DR: Implications for Clinical Practice

Anti-VEGF for DR: Implications for Clinical Practice

Arshad M. Khanani, MD, Nancy Holekamp, MD

Changing Treatment Paradigms for DR: Reviewing the Data

Changing Treatment Paradigms for DR: Reviewing the Data

Arshad M. Khanani, MD, Nancy Holekamp, MD

Reviewing the BOULEVARD Trial and RG7716

Reviewing the BOULEVARD Trial and RG7716

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Think Outside the Box: Treatment Options for DR

Think Outside the Box: Treatment Options for DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Key Takeaways for Treating Patients With DR

Anti-VEGF Therapy for Patients With Proliferative and Nonproliferative Disease

Anti-VEGF Therapy for Patients With Proliferative and Nonproliferative Disease

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

How to Manage Patient Buy-In for Anti-VEGF Therapy

How to Manage Patient Buy-In for Anti-VEGF Therapy

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

Take-Home Points From the BOULEVARD Trial

Take-Home Points From the BOULEVARD Trial

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

New Horizons for Treatment Options for DR

New Horizons for Treatment Options for DR

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

Medical Management of DR: Case Discussions

Kiss Case: Anti-VEGF Agents in a Case of PDR

Kiss Case: Anti-VEGF Agents in a Case of PDR

Caroline R. Baumal, MD, Charles C. Wykoff, MD, PhD, FACS, Szilard Kiss, MD

Chiang Case: Peripheral Neovascularization With PDR

Chiang Case: Peripheral Neovascularization With PDR

Allen Chiang, MD, Charles C. Wykoff, MD, PhD, FACS, Joseph M. Coney, MD

Coney Cases: Laser Versus Anti-VEGF Treatment for Diabetic Patients

Coney Cases: Laser Versus Anti-VEGF Treatment for Diabetic Patients

Allen Chiang, MD, Charles Fritch MD, Joseph M. Coney, MD

Baumal Case: How to Treat Active PDR Without DME

Baumal Case: How to Treat Active PDR Without DME

Back to All Videos

Think Outside the Box: Treatment Options for DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Rishi P. Singh, MD; Arshad M. Khanani, MD, MA; and Nancy Holekamp, MD, review why it is important to expand the current treatment options for patients with diabetic retinopathy (DR), along with what we can expect to come down the treatment pipeline in the next 5 years.

Posted: 9/27/2018

Keywords:

Updates in Changing Treatment Paradigms for DR

Please log in to leave a comment.